Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
Aidan McGlinchey, Olivier Govaere, Dawei Geng, et al.
JHEP Reports (2022) Vol. 4, Iss. 5, pp. 100477-100477
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Inter-organ crosstalk during development and progression of type 2 diabetes mellitus
Georgia Xourafa, Melis Korbmacher, Michael Roden
Nature Reviews Endocrinology (2023) Vol. 20, Iss. 1, pp. 27-49
Open Access | Times Cited: 95
Immunology of human fibrosis
Mallar Bhattacharya, Prakash Ramachandran
Nature Immunology (2023) Vol. 24, Iss. 9, pp. 1423-1433
Closed Access | Times Cited: 66
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 49
The Lipidomic Profile Discriminates Between MASLD and MetALD
Kai Markus Schneider, Feng Cao, Helen Huang, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 2
Differential sensing with arrays of de novo designed peptide assemblies
William Dawson, Kathryn L. Shelley, Jordan M. Fletcher, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 24
Artificial intelligence applied to ‘omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment
Soumita Ghosh, Xun Zhao, Mouaid Alim, et al.
Gut (2024), pp. gutjnl-331740
Open Access | Times Cited: 13
Ceramides are fuel gauges on the drive to cardiometabolic disease
Joseph L. Wilkerson, Sean M. Tatum, William L. Holland, et al.
Physiological Reviews (2024) Vol. 104, Iss. 3, pp. 1061-1119
Closed Access | Times Cited: 11
Diabetes as a risk factor for MASH progression
Sofiya Gancheva, Michael Roden, Laurent Castéra
Diabetes Research and Clinical Practice (2024) Vol. 217, pp. 111846-111846
Open Access | Times Cited: 11
Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics
Heng Yuan, Eun-Soo Jung, Soo-Wan Chae, et al.
Nutrients (2024) Vol. 16, Iss. 18, pp. 3061-3061
Open Access | Times Cited: 11
Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges
Anita Madir, Ivica Grgurević, Emmanuel Tsochatzis, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 4, pp. 290-307
Open Access | Times Cited: 10
Lipid Metabolism in MASLD and MASH: from mechanism to the clinic
Fabrizia Carli, Giuseppe Della Pepa, Silvia Sabatini, et al.
JHEP Reports (2024) Vol. 6, Iss. 12, pp. 101185-101185
Open Access | Times Cited: 10
Recent advances towards mass spectrometry-based clinical lipidomics
Samira Salihović, Santosh Lamichane, Tuulia Hyötyläinen, et al.
Current Opinion in Chemical Biology (2023) Vol. 76, pp. 102370-102370
Open Access | Times Cited: 18
Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective
Yansong Fu, Zhipeng Wang, Hong Qin
Metabolites (2024) Vol. 14, Iss. 4, pp. 218-218
Open Access | Times Cited: 8
Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease
María Martín-Grau, Daniel Monleón
World Journal of Clinical Cases (2023) Vol. 11, Iss. 6, pp. 1236-1244
Open Access | Times Cited: 12
Relationship of liver fat content with systemic metabolism and chronic complications in patients with type 2 diabetes mellitus
Weiwei Ren, Yunlu Feng, You‐Zhen Feng, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Systemic analysis of lipid metabolism from individuals to multi-organism systems
Samuel Furse, Carlos Martel, David F. Willer, et al.
Molecular Omics (2024)
Open Access | Times Cited: 4
Role of triggering receptor expressed on myeloid cells 2 in the pathogenesis of non-alcoholic fatty liver disease
Lihui Zhang, Sutong Liu, Qing Zhao, et al.
World Journal of Hepatology (2025) Vol. 17, Iss. 2
Closed Access
Hydroxysteroid 17β‐dehydrogenase 13 (Hsd17b13) knockdown attenuates liver steatosis in high‐fat diet obese mice
Shehroz Mahmood, Nicola Morrice, Dawn Thompson, et al.
Experimental Physiology (2025)
Open Access
Bifidobacterium bifidum 1007478 derived indole-3-lactic acid alleviates NASH via an aromatic hydrocarbon receptor-dependent pathway in zebrafish
Chao Tian, Shizhou Deng, Zhao Zhang, et al.
Life Sciences (2025), pp. 123557-123557
Closed Access
From Childhood Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Hyperlipidemia Through Oxidative Stress During Childhood
Siham Accacha, Julia Barillas-Cerritos, Ankita Srivastava, et al.
Metabolites (2025) Vol. 15, Iss. 5, pp. 287-287
Open Access
Schematic Assessment of Metabolic Signatures of Non-alcoholic Fatty Liver Disease by Bridging Endocrinology and Internal Medicine: A Precision Therapy-Based Meta-Analysis
Sakina Abbas, Zeeshan Hussain, Nek Bakht Asghar, et al.
Cureus (2025)
Open Access
Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022
Caroline Géhin, Stephen J. Fowler, Drupad K. Trivedi
Analytical Science Advances (2023) Vol. 4, Iss. 3-4, pp. 104-131
Open Access | Times Cited: 10
Exploring the Nutraceutical Potential of a Food–Medicine Compound for Metabolic-Associated Fatty Liver Disease via Lipidomics and Network Pharmacology
Yuru Deng, Jie Cui, Yuxuan Jiang, et al.
Foods (2025) Vol. 14, Iss. 7, pp. 1257-1257
Open Access
Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis
Oana Nicoară-Farcău, Juan José Lozano, Cristina Alonso, et al.
Hepatology (2023) Vol. 77, Iss. 6, pp. 2052-2062
Closed Access | Times Cited: 9
Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes
Asger Wretlind, Viktor Rotbain Curovic, Tommi Suvitaival, et al.
Diabetes (2023) Vol. 72, Iss. 10, pp. 1493-1501
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top